A_phase_I_trial_of_recombinant_human_interleukin-1_beta_alone_and_in_combination_with_myelosuppressive_doses_of_5-fluorouracil_in_patients_with_gastrointestinal_cancer._We_studied_escalating_doses_of_recombinant_human_interleukin-1_beta_(IL-1_beta)_alone_and_after_a_myelosuppressive_dose_of_5-fluorouracil_(5-FU)_in_patients_with_gastrointestinal_cancer._Transient_neutropenia,_monocytopenia,_and_lymphocytopenia_were_observed_followed_by_a_1.3-_to_6.0-fold_(mean,_3.46-fold)_dose-dependent_neutrophil_leukocytosis_(P_less_than_.00001)_on_the_days_of_IL-1_beta_administration._Increases_in_platelet_counts_were_observed_at_a_median_of_14_days_(range,_6_to_23)_after_IL-1_beta_administration._Transient_hypoglycemia,_rebound_hyperglycemia,_elevations_in_serum_cortisol,_and_C-reactive_protein_were_observed._Side_effects_included_fever,_rigors,_and_headache_in_the_majority_of_patients._Hypotension_was_observed_in_three_of_five_patients_at_the_highest_dose_level_(0.1_micrograms/kg)_and_was_dose-limiting._Fewer_days_of_neutropenia_were_noted_after_5-FU_plus_IL-1_beta_than_after_5-FU_alone;_however,_this_difference_did_not_reach_statistical_significance._These_data_show_that_IL-1_beta_has_stimulatory_effects_in_human_hematopoiesis.